tars-202306220001819790FALSE00018197902023-06-222023-06-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 22, 2023
_______________
TARSUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
_______________
| | | | | | | | | | | | | | |
| Delaware | 001-39614 | 81-4717861 | |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | |
15440 Laguna Canyon Road, Suite 160
Irvine, CA 92618
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (949) 409-9820
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | TARS | The Nasdaq Stock Market LLC Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 22, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 26, 2023 (the “Proxy Statement”).
At the close of business on April 19, 2023, the record date of the Annual Meeting, the Company had 26,803,307 shares of common stock outstanding and entitled to vote. The holders of a total of 22,180,888 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.
The following proposals were submitted to the Company’s stockholders at the Annual Meeting:
1.The election of three nominees as Class III directors to serve until the Company’s 2026 annual meeting of stockholders.
2.The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
The number of votes cast for and against or withheld and the number of abstentions and broker non-votes with respect to each matter voted upon, as applicable, are set forth below:
1. Board of Directors Election Results
The following nominees were elected to serve as Class III directors for a term that will continue until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified. The number of votes cast for and withheld and the number broker non-votes for each nominee were as follows:
| | | | | | | | | | | | | | | | | | | | |
| | | | | | |
Director Name | | Votes For | | Votes Withheld | | Broker Non-Votes |
Andrew Goldberg, M.D. | | 16,181,432 | | 1,018,819 | | 4,980,637 |
Scott Morrison | | 14,672,806 | | 2,527,445 | | 4,980,637 |
Wendy Yarno, MBA | | 16,555,347 | | 644,904 | | 4,980,637 |
The following directors, in addition to Dr. Goldberg, Mr. Morrison, and Ms. Yarno, will continue to serve as members of our Board of Directors until the expiration of their respective terms or until their respective successors have been duly elected and qualified: Bobak Azamian, M.D., Ph.D., Rosemary Crane, MBA, William Link, Ph.D., Bhaskar Chaudhuri, Ph.D., and Elizabeth Yeu-Lin, M.D.
2. Ratification of Ernst & Young LLP as our independent registered public accounting firm
Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The number of votes cast for and against and the number of abstentions for this proposal were as follows (there were no broker non-votes for this proposal):
| | | | | | | | | | | | | | |
| | | | |
Votes For | | Votes Against | | Abstain |
22,173,338 | | 7,065 | | 485 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | TARSUS PHARMACEUTICALS, INC. |
| | | | | | | |
| Date: | June 27, 2023 | |
| /s/ Jeffrey Farrow |
| | Jeffrey Farrow |
| | Chief Financial Officer and Chief Strategy Officer |